Literature DB >> 24030669

Feasibility of temporary protective embolization of normal liver tissue using degradable starch microspheres during radioembolization of liver tumours.

Carsten Meyer1, Claus Christian Pieper, Samer Ezziddin, Kai E Wilhelm, Hans Heinz Schild, Hojjat Ahmadzadehfar.   

Abstract

PURPOSE: To describe a new approach to protect nontarget healthy liver tissue using degradable starch microspheres (DSM) as a short-term embolizate during radioembolization of liver tumours with (90)Y microspheres.
METHODS: Between December 2011 and July 2012 radioembolization was performed in 54 patients. Five of these patients (three women, two men; mean age 67 years) underwent protective temporary embolization using DSM (EmboCept® S) of normal liver tissue that could not be excluded from the area treated by radioembolization through catheter repositioning. Clinical symptoms, laboratory findings, preinterventional imaging, and (99m)Tc-MAA and bremsstrahlung SPECT/CT, as well as baseline and follow-up imaging with (18)F-FDG PET/CT and MRI, were evaluated in relation to the technical and clinical success of the protective embolization.
RESULTS: Temporary embolization of arteries supplying normal liver tissue using DSM was technically successful in all five patients. (99m)Tc-MAA SPECT/CT performed in the first two patients after DSM injection showed no increased pulmonary shunting compared to the MAA test injection without DSM. Bremsstrahlung SPECT/CT after radioembolization demonstrated satisfactory irradiation of the tumour and successful protection of normal liver tissue. There were only mild hepatotoxic effects (grade 1) on laboratory follow-up examinations, and no adverse events associated with DSM embolization or radioembolization were recorded.
CONCLUSION: Temporary embolization with DSM before radioembolization is feasible and can effectively protect areas of normal liver tissue from irradiation and avoid permanent embolization if other methods such as catheter repositioning are not possible due to the location of the metastases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24030669     DOI: 10.1007/s00259-013-2550-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  33 in total

Review 1.  From the angio suite to the γ-camera: vascular mapping and 99mTc-MAA hepatic perfusion imaging before liver radioembolization--a comprehensive pictorial review.

Authors:  Livnat Uliel; Henry D Royal; Michael D Darcy; Darryl A Zuckerman; Akash Sharma; Nael E Saad
Journal:  J Nucl Med       Date:  2012-11       Impact factor: 10.057

2.  Toxicities after radioembolization with yttrium-90 SIR-spheres: incidence and contributing risk factors at a single center.

Authors:  Peachy Mae Piana; Carin F Gonsalves; Takami Sato; P Rani Anne; Jeffrey W McCann; Voichita Bar Ad; David J Eschelman; Laurence Parker; Laura A Doyle; Daniel B Brown
Journal:  J Vasc Interv Radiol       Date:  2011-07-20       Impact factor: 3.464

3.  Hepatic arterial infusion (HAI) with PEGylated liposomes containing 5-FU improves tumor control of liver metastases in a rat model.

Authors:  Uwe Pohlen; Heinz J Buhr; Gerd Berger; Jörg-Peter Ritz; Christoph Holmer
Journal:  Invest New Drugs       Date:  2011-03-01       Impact factor: 3.850

Review 4.  Radioembolization of liver tumors with yttrium-90 microspheres.

Authors:  Hojjat Ahmadzadehfar; Hans-Jürgen Biersack; Samer Ezziddin
Journal:  Semin Nucl Med       Date:  2010-03       Impact factor: 4.446

5.  99mTc-MAA/ 90Y-Bremsstrahlung SPECT/CT after simultaneous Tc-MAA/90Y-microsphere injection for immediate treatment monitoring and further therapy planning for radioembolization.

Authors:  Hojjat Ahmadzadehfar; Amir Sabet; Marianne Muckle; Kai Wilhelm; Karl Reichmann; Hans-Jürgen Biersack; Samer Ezziddin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-02-26       Impact factor: 9.236

Review 6.  Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications.

Authors:  Ravi Murthy; Rodolfo Nunez; Janio Szklaruk; William Erwin; David C Madoff; Sanjay Gupta; Kamran Ahrar; Michael J Wallace; Alan Cohen; Douglas M Coldwell; Andrew S Kennedy; Marshall E Hicks
Journal:  Radiographics       Date:  2005-10       Impact factor: 5.333

7.  Reduction of hepatic arterial flow by degradable microspheres in patients with liver tumor.

Authors:  L Thulin; G Tydén; B Nyberg; B Calissendorff; R Hultcrantz
Journal:  Acta Chir Scand       Date:  1986 Jun-Jul

8.  Selective internal radiotherapy (SIRT) of hepatic tumors: how to deal with the cystic artery.

Authors:  Jens M Theysohn; Stefan Müller; Jörg F Schlaak; Judith Ertle; Thomas W Schlosser; Andreas Bockisch; Thomas C Lauenstein
Journal:  Cardiovasc Intervent Radiol       Date:  2012-09-15       Impact factor: 2.740

9.  Intrahepatic biloma formation (bile duct necrosis) after transcatheter arterial chemoembolization.

Authors:  Ichiro Sakamoto; Soji Iwanaga; Kenji Nagaoki; Yojiro Matsuoka; Kazuto Ashizawa; Masataka Uetani; Toshio Fukuda; Tomoaki Okimoto; Sadayuki Okudaira; Katsuhisa Omagari; Kuniaki Hayashi; Naofumi Matsunaga
Journal:  AJR Am J Roentgenol       Date:  2003-07       Impact factor: 3.959

10.  Prophylactic embolization of the cystic artery before radioembolization: feasibility, safety, and outcomes.

Authors:  Justin P McWilliams; Stephen T Kee; Christopher T Loh; Edward W Lee; David M Liu
Journal:  Cardiovasc Intervent Radiol       Date:  2010-11-11       Impact factor: 2.740

View more
  6 in total

Review 1.  Polymeric materials for embolic and chemoembolic applications.

Authors:  Azadeh Poursaid; Mark Martin Jensen; Eugene Huo; Hamidreza Ghandehari
Journal:  J Control Release       Date:  2016-02-26       Impact factor: 9.776

Review 2.  Transarterial chemoembolization (TACE) for colorectal liver metastases--current status and critical review.

Authors:  Alexander Massmann; Thomas Rodt; Steffen Marquardt; Roland Seidel; Katrina Thomas; Frank Wacker; Götz M Richter; Hans U Kauczor; Arno Bücker; Philippe L Pereira; Christof M Sommer
Journal:  Langenbecks Arch Surg       Date:  2015-06-19       Impact factor: 3.445

3.  A review of 3D image-based dosimetry, technical considerations and emerging perspectives in 90Y microsphere therapy.

Authors:  Jim O' Doherty
Journal:  J Diagn Imaging Ther       Date:  2015-04-28

Review 4.  Side effects of yttrium-90 radioembolization.

Authors:  Ahsun Riaz; Rafia Awais; Riad Salem
Journal:  Front Oncol       Date:  2014-07-29       Impact factor: 6.244

5.  Intrahepatic flow diversion prior to segmental Yttrium-90 radioembolization for challenging tumor vasculature.

Authors:  Lindsay B Young; Marcin Kolber; Michael J King; Mona Ranade; Vivian L Bishay; Rahul S Patel; Francis S Nowakowski; Aaron M Fischman; Robert A Lookstein; Edward Kim
Journal:  J Interv Med       Date:  2022-05-21

Review 6.  Transarterial Radioembolization (TARE) Agents beyond 90Y-Microspheres.

Authors:  C Bouvry; X Palard; J Edeline; V Ardisson; P Loyer; E Garin; N Lepareur
Journal:  Biomed Res Int       Date:  2018-12-31       Impact factor: 3.246

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.